Recent News

• 11.05.2026 - Madrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with Rezdiffra
• 11.03.2026 - Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates
• 10.27.2026 - Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH
• 10.20.2026 - Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026
• 10.15.2026 - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
• 10.06.2026 - Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
• 09.16.2026 - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
• 09.02.2026 - Madrigal Pharmaceuticals to Participate in the  2026 Cantor Global Healthcare Conference
• 08.20.2026 - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
• 08.12.2026 - Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors

Recent Filings

• 11.03.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.03.2026 - 8-K Current report
• 11.03.2026 - EX-99.1 EX-99.1
• 09.28.2026 - 144 Report of proposed sale of securities
• 09.11.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.11.2026 - 144 Report of proposed sale of securities
• 09.09.2026 - 144 Report of proposed sale of securities
• 08.20.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.20.2026 - 144 Report of proposed sale of securities
• 08.18.2026 - 4 Statement of changes in beneficial ownership of securities